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ABSTRACT
Chronic graft-versus-host disease (CGVHD) is a major cause of morbidity and mortality following allogeneic bone
marrow transplantation (BMT). We studied 159 patients with CGVHD longitudinally to characterize the natural history
of CGVHD and identify reliable predictors of response and long-term mortality. Rates of response to treatment were
61%, 53%, and 50% at 6 months, 1 year, and 2 years, respectively. A high incidence of infections (7 of 1000 patient-days
at 0 to 6 months, 2.5 of 1000 patient-days at 6 months to 1 year, and 0.6 of 1000 patient-days at 1 to 2 years) was observed.
After a median follow-up of 8.4 years, an overall survival rate of 40% was observed. The overall survival rate was 63% (95%
confidence interval [CI], 56%-71%) at 1 year, 51% (95% CI, 43%-59%) at 2 years, and 39% (95% CI, 31%-47%) at 10
years. In multivariate analysis, age older than 20 years (RR  1.5; 95% CI, 0.9%-2.5%; P  .09), progressive onset of
CGVHD (RR  1.6; 95% CI, 1.0%-2.4%; P  .04), platelet count of <100,000/L (RR  2.1; 95% CI, 1.3%-3.4%; P 
.001), and GI involvement (RR  1.5; 95% CI, 1.0%-2.4%; P  .05) were associated with increased mortality. Among
patients surviving more than 6 months, no response (RR  4.5; 95% CI, 1.9%-10.5%; P  .0006) and partial response
(RR  2.5; 95% CI, 1.1%-6.1%; P  .04) to treatment at 6 months also were significant predictors of mortality. The
prevalence of active CGVHD was 33% at 2 years. However, the cumulative incidence of successful discontinuation of
therapy was only 13% at 2 years. Among patients with clinical resolution of CGVHD, only 18% were off immunosup-
pressive therapy by 2 years, and 89% by 4 years. Despite high initial response rates, a large majority of patients had active
disease requiring prolonged immunosuppression. This requires improved infection prevention for a longer time. Recog-
nition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to
be identified to improve survival and limit toxicity of prolonged immunosuppression.
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INTRODUCTION
Chronic graft-versus-host disease (CGVHD) is a late
complication of bone marrow transplantation (BMT) charac-
terized by a connective tissue–like disease usually, but not
always, occurring more than 100 days after blood stem cell or
bone marrow transplantation. Clinically, CGVHD may be
manifest by involvement of the skin, oral mucosa, gastroin-
testinal (GI) tract, eyes, liver, lungs, and joints [1]. CGVHD
develops in 30% to 60% of transplantation survivors [2,3] and
remains a major cause of morbidity and mortality after allo-
geneic BMT. The major cause of death in patients with
CGVHD is infection due to continuing immunodeﬁciency
[1,4]. Poor prognostic factors that have been identiﬁed in-
clude thrombocytopenia (platelet count  100,000/L), in-
creased age, lichenoid skin pathology, liver involvement, and
progressive presentation of CGVHD [5,6] (CGVHD devel-
oping before resolution of acute GVHD).
The survival rate in patients with CGVHD remains poor. We
conducted a prospective cohort study of patients with CGVHD to
characterize the clinical presentation and course of the disease and
identify groups at high risk for development of complications
(infections, poor response to treatment, or mortality). We report
their long-term follow-up, prevalence of CGVHD, and prolonged
duration of immunosuppressive therapy.
METHODS
Eligibility Criteria
Patients who underwent allogeneic BMT at the University
of Minnesota between November 1987 and August 1993 and
Biology of Blood and Marrow Transplantation 9:38-45 (2003)
 2003 American Society for Blood and Marrow Transplantation
1083-8791/03/0901-0004$35.00/0
doi: 10.1053/bbmt.2003.50003
38
who developed CGVHDwere eligible for inclusion in the study.
The cohort includes 159 patients with symptomatic CGVHD.
CGVHD was classiﬁed as single or advanced with multi-organ
disease. The diagnosis and organ involvement with CGVHD
was based on standard clinical and/or histological criteria. GI
and liver involvement with CGVHD were deﬁned based on
symptomatology and positive laboratory tests or positive biopsy
results (positive malabsorption tests or increased liver enzymes).
In all cases, obstruction, infections, and drugs were ruled out as
possible causes.
Treatment Plan
Limited skin involvement was treated with topical steroids
(0.1% triamcinolone cream to body, 1% hydrocortisone cream
to face) 3 times a day. Patients with only hepatic involvement
(bilirubin  3 mg/dL) did not receive therapy but were closely
observed for disease progression.
Therapy for Symptomatic CGVHD. All patients (n  159)
with more extensive CGVHD resulting in clinical symptoms
received initial therapy with high-dose methylprednisone given
at a dosage of 15 mg/kg as an intravenous (IV) injection weekly
for 8 weeks.
Patients enrolled in the initial cohort between November
1987 and November 1988 (n  22) also received treatment with
prednisone at a dosage of 0.5 mg/kg orally every other day and
azathioprine at a dosage of 1 mg/kg orally each day. If patients
developed an absolute neutrophil count (ANC) of 1000 to
1500/L and/or a platelet count of 50,000 to 80,000/L the
dosage of azathioprine was reduced to 0.5 mg/kg/d whereas
azathioprine was withheld for ANC of 1000/L and platelets
of 50,000/L.
Patients enrolled in the cohort from November 1988 to
August 1993 (n  137) were to receive cyclosporine (CSA) in
addition to azathioprine and prednisone as above. CSA was
started at 6.25 mg/kg orally twice daily (or 1.5 mg/kg IV twice
daily) with the dose modiﬁed to maintain trough levels  200
ng/mL. However, due to tolerance and clinical toxicities, a total
of 55 patients received prednisone and azathioprine, 57 patients
received prednisone alone, 16 patients received CSA in addition
to prednisone and azathioprine, 25 patients were treated with
prednisone and CSA, 3 patients received prednisone and thalid-
omide, and 3 patients received other agents. In patients with no
response to the initial 8 weeks of therapy or progression after
initial stabilization or response, methylprednisone was given at a
dosage of 15 mg/kg/d IV for 5 days, and oral prednisone was
increased to 1 mg/kg/d for 6 weeks, then tapered over a 3-month
period to 0.5 mg/kg/d on alternate days. Therapy was continued
until 9 months following the last clinical evidence of active
CGVHD followed by a taper over 2 to 3 months.
Measurement of Response. Patients returned for evaluation at
the University of Minnesota at 6 months, 1 year, and 2 years
after enrollment into the study and approximately yearly there-
after. Because patients did not always return to the transplanta-
tion center on the scheduled dates, window periods were used to
maximize the completeness of evaluation. For the 6-month visit,
the evaluation window period was between 3 and 9 months from
enrollment. For the 1- and 2-year visits, window periods of 9 to
15 months and 21 to 27 months, respectively, were used. All
patients included in the study were enrolled at least 6 months
prior to study termination. The median follow-up of surviving
patients was 8.4 years (range, 0.7-13.4 years).
Response to therapy was graded as complete response (CR)
deﬁned as resolution of all signs and symptoms of CGVHD.
Partial response (PR) was deﬁned as improvement in 1 or more
organs of involvement and no evidence of worsening in any
organ. Flare included patients with PR or CR followed by
worsening of CGVHD that was less severe than at the baseline
evaluation. No response was deﬁned as either progression of
CGVHD to worse than at baseline evaluation, or no improve-
ment in CGVHD after 6 months of therapy. Prevalence of
CGVHD was deﬁned as proportion of all patients with active
CGVHD among surviving patients. Improvement or worsening
of disease were determined through both subjective and objec-
tive criteria. Subjective criteria were symptomatic change in
cough, dyspnea, anorexia, nausea, vomiting, diarrhea, arthralgia,
or dry eyes. Objective criteria included physical examination of
skin, oral mucosa, weight change and/or liver function tests,
pulmonary function tests, Schirmer’s test, biopsies, and radio-
logical studies. All patients who died of complications related to
CGVHD (infections or multi-organ dysfunction) were consid-
ered at subsequent time points as non-responders.
STATISTICAL ANALYSIS
The study was designed as a prospective cohort study; 159
patients with CGVHD were enrolled and followed longitudi-
nally. A database was created to include all patients with
CGVHD and variables such as baseline demographic data, type
of onset of CGVHD, dates of diagnosis and treatment, organ
involvement at diagnosis, complications, and causes of death/
relapse. Data collection and entry was carried out by trained
personnel. This was supplemented by chart reviews for speciﬁc
organ involvement, complications, and continuation of therapy
at 6 months, 1 year, and 2 years from diagnosis. Grading of
response was performed without knowledge of the subsequent
survival status. Statistical analysis of response was performed
before analysis of survival to maintain blinding.
Response to Therapy
Response to therapy was assessed at 6 months, 1 year, and 2
years.
Predictors of Response. Eleven potential predictors were eval-
uated. These included recipient age at transplantation, gender of
recipient and donor, cytomegalovirus (CMV) serological status
of recipient and donor, type of transplant (allogeneic sibling
versus unrelated donor), HLA mismatch, prior presence and
clinical grade of acute GVHD, onset of CGVHD (de novo,
progressive, or quiescent), organ involvement with CGVHD
(eyes, mouth, skin, lungs, GI, and liver), platelet count, serum
bilirubin level, and alanine aminotransferase (ALT) level at
baseline. Pearson’s chi-square test was used in the univariate
analyses to compare the proportion of subjects with response to
therapy within each category of potential predictors. Multivar-
iate logistic regression was used to evaluate the independent
effect of study variables on treatment response. A stepwise re-
gression with forward selection was used. A signiﬁcance level of
.1 was used to enter into the model and .15 to stay in the model.
Survival
Patient survival was determined using the Kaplan-Meier [7]
estimation with 95% conﬁdence intervals (CIs) derived from
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standard errors. Patients were censored at the date of last con-
tact. Survival was estimated from onset of CGVHD.
Predictors of Mortality. Potential factors associated with mor-
tality were studied. The Kaplan-Meier product limit method [7]
and log-rank testing was used to compare survival in the subsets
and the Cox regression model [8] was used to assess the indepen-
dent effect of the predictors on survival as well as any potential
confounding on the effect of treatment. A stepwise regression with
forward selection was used. A signiﬁcance level of .1 was used to
enter into the model and .15 to stay in the model. Acute GVHD
(grade III and IV) was excluded from the model because of colin-
earity between progressive onset and acute GVHD. Cumulative
incidence rates were used to estimate the probability of discontin-
uation of all immunosuppressive treatment [9] over the complete
period of follow-up.
Complications after Transplantation
Complications studied included hypertension, hyperglyce-
mia requiring treatment, seizures, thrombotic thrombocytope-
nic purpura, avascular necrosis, and infections.
Infections Following BMT. Clinically signiﬁcant infections
with microbiological conﬁrmation or requiring systemic antibi-
otic therapy or hospitalization were tabulated during the ﬁrst 2
years of therapy. To account for multiple events, density inci-
dence was used to describe the total rate of infections. It was
deﬁned as the total number of infections per 1000 patient-days
of observation.
RESULTS
During the 4.9 years of patient enrollment, the overall
incidence of CGVHD among patients undergoing allogeneic
BMT was 44%. Table 1 lists the characteristics of the patients
with CGVHD. The median age at transplantation was 30 years.
Of the recipients, 33% received a transplant from an unrelated
donor. Progressive onset of disease was seen in 45% of patients.
The median platelet count at study entry was 72,000/L and
30% of patients had liver involvement at diagnosis.
Table 1. Clinical Characteristics at Study Entry
Patient Demographics Number %
Number of patients 159 100
Diagnosis
Acute leukemia 42 26.4
Chronic myelogenous leukemia 66 41.5
Other malignancies 15 9.5
Non-malignant diseases 36 22.6
Median age, y (range) 29.5 (.6-54)
<20 y 51 32.1
20-39 y 71 44.6
>40 y 37 23.3
Donor/recipient sex mismatch
Male recipient with female donor 55 34.6
Donor/recipient cytomegalovirus sero
status (either or both positive) 108 69.2
Type of transplant
Sibling donor 107 67.3
Unrelated donor 52 32.7
HLA mismatch 38 23.9
HLA match 121 76.1
Conditioning regimens
Total body irradiation plus
cyclophosphamide 107 67.3
Busulfan plus cyclophosphamide 11 6.9
Others 41 25.8
Prophylaxis for acute GVHD
Methotrexate plus ATG plus prednisone 63 39.6
Methotrexate plus CSA 37 23.3
T-cell depletion 7 4.4
Others 52 32.7
Acute GVHD
None 19 11.9
Grade I-II acute GVHD 86 54.1
Grade III-IV acute GVHD 54 34
Onset of CGVHD
De novo 18 11.5
Quiescent 68 43.3
Progressive 71 45.2
Time to treatment of CGVHD (days
posttransplantation): median (range) 141 (52-775)
Organ involvement
Skin 119 74.8
Oral 99 62.3
Liver 46 28.9
GI 60 37.7
Lungs 17 10.7
Eyes 35 22.0
Laboratory data at onset of CGVHD
Platelet count (103/L) median (range) 72 (10-454)
N (%) with platelet count < 100,000/L 90 (59.2)
White blood cell count/L median
(range) 4800 (600-9500)
Bilirubin > 3 mg/dL 26 (17.7)
Alanine aminotransferase > 250 units/dL 26 (18.3)
ATG indicates antithymocyte globulin.
Table 2. Patient Evaluability over Time
Time Post-Diagnosis
of CGVHD n (%)
Evaluable
NEAlive Dead
6 mo, n  155 (97.5%) 131 24 3 relapsed, 1 NE
1 y, n  148 (93.1%) 107 41 8 relapsed, 3 NE
2 y, n  141 (88.7%) 82 59 12 relapsed, 6 NE
NE indicates not evaluable (secondary to relapsed disease or insuf-
ﬁcient data within deﬁned time windows for evaluation).
Note. All patients who died of causes other than relapse were evalu-
able for response.
Table 3. Frequency of Response
Response 6 mo N (%) 1 y N (%) 2 y N (%)
CR 58 (37.4) 44 (29.7) 55 (39.0)
PR 37 (23.9) 34 (23) 16 (11.3)
NR 60 (38.7) 53 (35.8) 64 (45.4)
Flare — 17 (11.5) 6 (4.3)
CR plus PR 95 (61.3) 78 (52.7) 71 (50.4)
NR plus Flare 60 (38.7) 70 (47.3) 70 (49.6)
NR indicates no response.
Note. Patients who died of causes other than relapse were considered
nonresponders.
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Response to Therapy
As shown in Tables 2 and 3, the response to therapy was
evaluated at 6 months, 1 year, and 2 years from diagnosis. Of the
159 patients enrolled, the number of patients evaluable for
response was 155, 148, and 141 at 6 months, 1 year, and 2 years,
respectively. Twelve patients (8%) relapsed and died within 2
years and did not have response assessed. Of these, 3 patients
had relapsed by 6 months, 8 patients had relapsed by 1 year, and
12 patients had relapsed by 2 years. One, 3, and 6 patients had
evaluations performed only outside the deﬁned window periods
for evaluation at 6 months, 1 year, and 2 years, respectively.
Complete plus partial responses were observed in 61%, 53%,
and 50% of patients at 6 months, 1 year, and 2 years, respec-
tively. Complete response was seen in 30% of patients by 1 year
and 39% of patients by 2 years. Only 12% of responders at 6
months experienced a ﬂare of the disease by 1 year.
Predictors of Response
We analyzed 11 clinical factors as potential predictors of
response at 2 years. In univariate analysis, responses were more
frequent in patients with de novo/quiescent onset of CGVHD
(60% versus 39%; P  .01) and platelet count of 100,000/L
(64% versus 41%; P  .01). In the multivariate analysis, de
novo/quiescent onset of disease (odds ratio [OR] 2.3; P  .03)
and platelet count of 100,000/L (OR 2; P  .06) remained
signiﬁcant predictors of more frequent response. In addition,
age of 20 years or older (OR 2.1; P  .08) and absence of GI
involvement with CGVHD (OR 1.9; P  .08) also were inde-
pendent predictors of more frequent response with marginal
signiﬁcance (Table 4). Recipients of transplants from unrelated
donors versus related donors had similar responses.
Survival
After a median follow-up of 8.4 years (range, 0.7-13.4 years),
an overall survival rate of 40% was observed. The survival rate was
63% (95% CI, 56%-71%) at 1 year, 51% (95% CI, 43%-59%) at
2 years, 40% (95% CI, 32%-48%) at 8 years, and 39% (95% CI,
31%-47%) at 10 years (Figure 1). Overall, 95 patients died. Most
deaths (86%) were observed within 2 years of onset, but deaths
continued to occur up to 8.6 years after diagnosis. Nearly all (86%)
patients died of complications related to CGVHD (Table 5). In-
fections accounted for 63% of deaths in patients with active
CGVHD (50% due to bacterial infections, 35% due to viral infec-
tions, and 15% due to fungal infections) and 9% of deaths in
patients without active disease. (Patients with clinical resolution of
CGVHDwho were off all immunosuppression.) Two patients died
of a second malignancy and 2 patients died of complications unre-
lated to transplantation. Seventeen patients relapsed and died (13
within 2 years of CGVHD). Thirteen late deaths were observed
(beyond 2 years from diagnosis). Of these, 11 patients died of
complications related to CGVHD. Two of these 11 patients died
of a second malignancy.
Predictors of Mortality
In univariate analysis, several factors were associated with
poor survival. Progressive onset of CGVHD (P  .01), platelet
count of 100,000/L (P  .01), involvement of GI tract with
CGVHD (P  .01), bilirubin of 3 mg/dL, and no CR or PR
at 6 months (P  .01) were each signiﬁcant predictors of poor
Table 4. Predictors of Response: Multivariate Analysis
Predictor OR (CI) P
De novo plus quiescent versus progressive onset 2.3 (1.08-4.85) .03
Platelets > 100,000/L versus <100,000/L 2.0 (0.95-4.38) .06
Age younger than 20 y versus 20 y or older 2.1 (0.92-4.73) .08
No GI involvement versus GI involvement 1.9 (0.9-4.08) .08
Note. Logistic regression showing the independent OR and 95% CI
favoring CR or PR at 2 years.
Figure 1. Overall and relapse-free survival after onset of CGVHD estimated using Kaplan-Meier method.
Table 5. Causes of Non-Relapse Mortality
Cause Number %
CGVHD 67 85.9
CGVHD plus infection 42 62.7
CGVHD plus other complications 13 19.4
CGVHD 12 17.9
Infection 7 8.9
New malignancy 2 2.6
Other 2 2.6
Note. Other complications included causes of death unrelated to
transplant or CGVHD. Infection includes infectious etiology as a cause
of death in patients without active CGVHD who were off all immuno-
suppressive therapy.
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survival. Patients with any combination of 3 or more of these
high-risk factors had a 10-year survival rate of only 11%,
whereas patients with 0 or 1 risk factor had a 10-year survival
rate of 72% and 52%, respectively (Figure 2).
In the multivariate analysis, platelets  100,000/L (RR
2.1; P  .001), progressive onset of disease (RR 1.6; P  .04),
and involvement of GI tract with CGVHD (RR 1.5; P  .05)
were independently signiﬁcant predictors of poor survival (Ta-
ble 6). Older age (20 years or older) (RR 1.5; P  .09) was an
important predictor with marginal statistical signiﬁcance. Pa-
Table 6. Predictors of Poor Survival: Multivariate Analysis
Predictor Relative Risk (CI) P
Age 20 or older 1.5 (0.9-2.5) .09
Progressive onset 1.6 (1.0-2.4) .04
Platelets < 100,000/L 2.1 (1.3-3.4) .001
GI involvement 1.5 (1.0-2.4) .05
Note. The relative risk (95% CI) shown is of mortality following
therapy for CGVHD derived from Cox multiple regression analysis.
Table 7. Predictors of Poor Survival: Multivariate Analysis
(Patients Surviving  6 Months)
Predictor Relative Risk (CI) P
NR 4.5 (1.9-10.5) .0006
PR 2.5 (1.1-6.1) .04
Age 20 y or older 1.8 (0.9-3.9) .09
Progressive onset 2.1 (1.1-4.1) .03
GI involvement 2.2 (1.1-4.4) .02
Abbreviations: NR, PR, no response or partial responses at 6 month
evaluation.
Note. Shown is the relative risk (95% CI) of mortality following
therapy for CGVHD derived from Cox multiple regression analysis.
Figure 2. Predictors of survival: univariate analysis. Analysis by number of risk factors at onset of CGVHD is shown in panel F. Risk factors considered
include those shown in the other panels, A-E, as statistically signiﬁcant.
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tients with progressive onset of disease had more frequent in-
volvement of the GI tract (45.8 versus 31%; P .06). Even after
stratiﬁcation of the analysis by onset of disease (progressive
versus de novo/quiescent), GI involvement remained an inde-
pendent predictor of poor survival (RR 1.5; P  .06). In a
separate regression analysis (Table 7) excluding patients who
died within 6 months of study entry, no response (RR 4.5; P 
.0006) and partial response (RR 2.5; P  .04) at 6 months also
were signiﬁcant independent predictors of poor survival.
Prevalence of CGVHD
The prevalence of CGVHD (persistence of active CGVHD
among surviving patients) was evaluated over time. The assess-
ment of prevalence incorporates both ﬂares and persistence of
CGVHD and as the prevalence decreases it reﬂects a clinical
cure of CGVHD. The prevalence was 56% at 6 months, 60% at
1 year, and 33% at 2 years.
Complications of CGVHD
Hypertension (19%) and hyperglycemia (13%) were the
most frequent noninfectious complications observed among pa-
tients treated for CGVHD with immunosuppressive therapy
(159 patients). Seizures, thrombotic thrombocytopenic purpura,
and avascular necrosis were observed at a frequency of 8%, 9%,
and 6%, respectively (Table 8).
Infections
In all patients, a high incidence density of infections (7 of
1000 patient-days at 6 months, 2.4 of 1000 patient-days at 1
year, and 0.6 of 1000 patient-days at 2 years) was observed.
Bacterial infections were most frequent across all time periods
(3.4 of 1000 patient-days at 6 months, 1.2 of 1000 patient-days
at 1 year, and 0.3 of 1000 patient-days at 2 years) (Figure 3).
Table 8. Complications of Therapy
Complication Number %
Hypertension 30 18.8
Hyperglycemia 20 12.6
Seizures 13 8.2
TTP/HUS 14 8.8
Avascular necrosis 10 6.3
Abbreviations: TTP/HUS, thrombotic thrombocytopenic purpura/
hemolytic uremic syndrome.
Note. Proportion of patients experiencing complications among all
patients receiving immunosuppressive therapy (n  159).
Figure 3. Infections complicating CGVHD. These panels show the incidence density of bacterial, viral, and fungal infections expressed as infections
per 1000 patient-days (p-d) of follow-up alive. In panel A, the assessments of infections over the 2-year observation period are shown.
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Duration of Treatment and Outcome
Seventy-seven patients survived 2 years or more after diag-
nosis of CGVHD. At 2 years after diagnosis, 64 patients were
still receiving immunosuppression. Of these, 36 patients could
be tapered off medications by 3 years. Twenty-eight patients
required immunosuppression for 4 or more years. The cumula-
tive incidence of successful discontinuation of immunosuppres-
sive treatment was 13% at 2 years, 47% at 3 years, and 75% at
4 years. From 4 to 10 years, 25% of patients were still on
treatment (Figure 4). By 2 years, 55 patients had complete
clinical resolution of CGVHD. Of these, only 10 patients (18%)
were able to discontinue immunosuppression by 2 years. Forty
patients (73%) discontinued therapy by 3 years and 51 patients
(93%) discontinued therapy by 4 years.
DISCUSSION
CGVHD remains the major cause of late morbidity and
mortality following allogeneic transplantation. We postulated
that examination of clinical presentation of CGVHD, response
to treatment, medical complications, and long-term survival
would allow clariﬁcation of the natural history of CGVHD and
lead to identiﬁcation of reliable predictors of response and
mortality.
In this high-risk cohort, we observed good initial response
rates of 61% at 6 months. Our overall response rates of 53% and
50% at 1 year and 2 years, respectively, are similar to those
observed in previous studies. We observed CRs in 30% and 39%
at 1 and 2 years, respectively. Overall responses of 56% and 71%
were reported in high-risk (platelet count  100,000/L) and
refractory (to prednisone with or without azathioprine) disease,
respectively, by Sullivan et al. in patients receiving alternating
day CSA and prednisone [10]. CRs were reported in 33% of
high-risk patients and 19% of initially resistant patients. Sullivan
et al. had reported an overall response rate of 55% and a CR rate
of 30% in patients treated with prednisone and azathioprine or
prednisone alone for treatment of CGVHD [5]. A higher re-
sponse rate of 80% was observed in our randomized clinical trial
of thalidomide [11]. The difference may reﬂect differences in
the patient populations as well as different time periods of study.
More frequent high-risk features were seen in the current study
(progressive onset of CGVHD was seen in 45% of patients in
the current study versus 17% in our randomized thalidomide
trial; platelet count  100,000/L in 59% versus 37% of pa-
tients, respectively).
We evaluated responses that persisted at or beyond 2 years,
to evaluate the frequency of sustained responses during tapering
of immunosuppression. At 2 years we observed a high rate of
sustained response of 50%. Initial treatment responses were
continuing and durable in the majority of responding patients
with CGVHD; ﬂares were uncommon beyond 2 years.
Few patients died beyond the ﬁrst 2 years and with a median
follow-up of 8.4 years 40% survive, similar to estimates reported
in other studies. Sullivan et al. reported survival estimates of
61%, 47%, and 26% after transplantation in patients receiving
prednisone and placebo, prednisone and azathioprine, and pred-
nisone alone after a median follow up of 5.6, 6, and 5.5 years,
respectively [5]. Treatment with CSA and prednisone led to
survival rates of 58% after primary therapy and 70% for salvage
therapy after a median follow-up of 41 and 52 months, respec-
tively [10], from the time of transplantation rather than from the
onset of CGVHD. Similar to the current report, Akpek et al.
[12] reported a survival rate of 51% at 10 years after onset of
CGVHD and Wingard et al. [6] reported a survival rate of 52%
with a median follow-up of 3.7 years after onset of CGVHD
with a projected actuarial survival at 10 years of 42%.
We evaluated potential prognostic factors associated with
improved response or survival. Among these, progressive onset,
thrombocytopenia, and age 20 years or older have been cited as
potential predictors of poor survival in other studies [5,6,11,12].
Akpek et al. [12] reported extensive skin involvement to be a
signiﬁcant predictor of poor survival. However, in our study, the
extent of skin involvement was not evaluable and overall skin
involvement was not a signiﬁcant predictor of survival. Skin
histology also was not evaluated as a potential predictor of
survival.
In addition, we found that involvement of the GI tract was
important in predicting survival. Diagnosis of GI involvement
was based on clinical and/or pathological criteria. Not all pa-
tients underwent biopsies. However, other causes of similar
Figure 4. Graphs showing the cumulative incidence of discontinuation of immunosuppressive therapy for CGVHD in patients surviving more than
2 years. Panels A and B show the cumulative incidence of discontinuation of therapy for all patients and for patients with CR, respectively.
Immunosuppression was routinely administered for 9 months beyond the clinical resolution of CGVHD.
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symptomatology (drugs, infection, or mechanical) were ruled
out in all patients. GI involvement was associated with progres-
sive onset of disease (45.8% versus 31%; P  .06), a strong
predictor of poor survival. However, both progressive onset and
GI involvement were independent signiﬁcant predictors of sur-
vival in the multivariate analysis. Even after stratiﬁcation of the
analysis by onset of disease, GI involvement remained an inde-
pendent predictor of poor survival, suggesting that GI involve-
ment is a powerful predictor of poor survival. Early response to
therapy also was important in predicting survival. Patients with
no response or PR at 6 months had a markedly worse survival
than patients with early CR. If conﬁrmed in other series, this
suggests that incomplete initial response can identify a high-risk
group that might beneﬁt from intensiﬁed treatment.
A very high density incidence of infections was observed in
this cohort, with most infections occurring in the ﬁrst 6 months.
Infections were the leading cause of mortality from CGVHD
[4,13]. Beyond the choice of immunosuppression, effective pro-
phylaxis against infection is a critical component of CGVHD
management. Vogelsang suggested that in spite of completing
immunosuppressive therapy, poor splenic function persists, and,
for this reason, recommended long-term penicillin prophylaxis
[14].
Although immunosuppression was routinely administered
for 9 months beyond the resolution of GVHD, 87% of patients
required treatment for more than 2 years with a substantial
number of patients having active and continuing CGVHD be-
yond 4 years of treatment. Among patients with clinical resolu-
tion of CGVHD, only 18% were able to discontinue therapy by
2 years and 25% required 4 or more years of immunosuppressive
therapy. These data suggest that, despite good initial response
rates, a substantial number of patients had active disease requir-
ing prolonged immunosuppression. This underscores the re-
quirement for effective infection prophylaxis for all patients and
especially this group needing long-term therapy. The noninfec-
tious morbidity of chronic immunosuppression (impaired bone
density, joint necrosis, nephrotoxicity, and second cancers) also
must be accounted for in evaluating the cumulative toxicity of
ongoing CGVHD.
Recognition of a high-risk group (age 20 years or older,
progressive onset of disease, platelets  100,000/L, GI in-
volvement, and those without a complete response after 6
months) should facilitate assignment of more intensiﬁed regi-
mens to these patients. Better treatment regimens need to be
identiﬁed to improve survival in patients with CGVHD. Newer
treatment strategies should focus on a high-risk group and on
those requiring prolonged immunosuppression.
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